With global PMIs pointing to steady, if uneven, growth and inflation pressures generally easing, investors are starting to pay closer attention to selective risk rather than broad market moves. Cash remains king for smaller companies, especially penny stocks, where many stumble when funding dries up. The Elite Penny Stocks screener focuses only on stocks with the balance sheets to pursue their targets, which can help you narrow your search to higher quality opportunities in a volatile corner of the market. In this article you will see three of the most interesting stocks from the Elite Penny Stocks screener.

Yatsen Holding (YSG)

Overview: Yatsen Holding is a Guangzhou based beauty company that develops and sells color cosmetics, skincare and beauty tools in China through a mix of online platforms and offline stores, using brands such as Perfect Diary, Little Ondine, Pink Bear, Galénic, DR.WU, Eve Lom and EANTiM to target different price points and customer needs.

Operations: Yatsen Holding currently generates all of its CN¥4.49b in revenue from customers in the People’s Republic of China.

Market Cap: US$306.7m

Yatsen Holding is on many investors’ radar because it combines fast growing skincare brands and a strong online to offline presence with a share price that still reflects its unprofitable status. Recent revenue of about CN¥1,021m for Q1 2026 and a new partnership to place Perfect Diary in Sephora China stores give the business more scale and access to higher spending customers, even though the company reported a net loss of CN¥60.51m and carries higher risk external funding. Analyst expectations for faster earnings growth and a low P/S multiple indicate that the market is still cautious, which gives you an opportunity to weigh the potential upside from an earnings recovery against the risks around competition and marketing spend.

Yatsen Holding’s mix of fast growing skincare brands and cautious market expectations may be masking the real story. Get the context behind that low P/S and earnings gap with the analyst forecasts for Yatsen Holding

MediciNova (MNOV)

Overview: MediciNova is a La Jolla based biopharmaceutical company developing small molecule drugs for serious conditions with limited treatment options, including neurological diseases such as progressive multiple sclerosis and ALS, certain cancers like glioblastoma, and liver and metabolic disorders linked to nonalcoholic fatty liver disease and high triglycerides.

Market Cap: US$65.5m

MediciNova attracts attention because it sits at the high risk, high potential end of the Elite Penny Stocks screener. The company is still loss making on a very small revenue base of about US$0.19m for Q1 2026 and relies heavily on external funding, so setbacks in its trials or delays in partnerships could hit the stock hard. At the same time, the pipeline has several shots on goal, with patents around MN-166 combinations and late stage work on MN-001 in areas like NAFLD and hypertriglyceridemia. For investors who can handle biotech volatility, MediciNova offers a focused story built around experienced leadership and upcoming clinical readouts that could materially change how the market values the business.

MediciNova’s small revenue base and pipeline of late stage shots on goal leave a big question about how the story could reprice if sentiment shifts. Get the full picture in the analyst forecasts for MediciNova

Clover Health Investments (CLOV)

Overview: Clover Health Investments provides Medicare Advantage health plans in the United States and offers both preferred provider organization and health maintenance organization options for eligible seniors, while its Clover Assistant software supports doctors by flagging and managing chronic conditions at the point of care.

Operations: Clover Health Investments generates about US$2.21b in revenue from its insurance business in the United States.

Market Cap: US$2.28b

Clover Health Investments is drawing interest because it combines a technology supported care model, through Clover Assistant, with a focused Medicare Advantage offering in a market where enrollment is expanding. Revenue of US$749.19m and net income of US$27.33m in Q1 2026 show that the business has already moved from losses to profitability. However, the stock still trades on a low P/S multiple and is identified as trading well below some fair value estimates. At the same time, investors need to weigh rising medical and pharmacy costs, reliance on external borrowing and ongoing regulatory changes, which could squeeze margins at a time when expectations for strong earnings growth are building.

Clover Health Investments appears to be a profitability story that the market has not fully priced, with that low P/S hinting at something investors might be missing. See how revenue, earnings and expectations line up in the analyst forecasts for Clover Health Investments

The three elite penny stocks in this article are only a small sample, and the full Elite Penny Stocks screener surfaces 17 more companies with equally compelling balance sheets and stories. Use Simply Wall St to identify, analyze and filter for the exact catalysts, funding runways and earnings narratives that match your highest conviction ideas so you can focus on the opportunities that fit your playbook.

Take Control of Your Investment Journey

If Clover Health Investments or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly

The fastest moves often start quietly, while momentum is building and prices have not yet broken out. Scan fresh ideas that are under the radar for now and consider your options early.

• Track cash rich companies with room to grow and quickly sort them using the curated list of solid balance sheet and fundamentals (49 results) before the crowd catches on.
• Explore potential income opportunities by focusing on resilient payers in the hand picked 7 dividend fortresses while yields still look appealing.
• Identify early price strength in carefully filtered 82 resilient stocks with low risk scores before sellers exhaust themselves and buyers begin to influence valuations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.